清气化痰丸加减联合丙卡特罗治疗痰热蕴肺证支气管哮喘的临床效果及对炎性因子的影响  

Clinical Effect of Qingqi Huatan Pill Combined with Procatterol in the Treatment of Bronchial Asthma with Syndrome of Phlegm⁃heat Obstructing Lung and Its Effect on Inflammatory Factors

作　　者：观云 武蕾[2] 彭飞飞 张萱 GUAN Yun;WU Lei;PENG Feifei;ZHANG Xuan(Department of Respiratory and Critical Care Medicine,Hebei Hospital of Tradi-tional Chinese Medicine,Shijiazhuang 050013,China;Department of Respiratory Medicine,Hebei Hospital of Tradi-tional Chinese Medicine,Shijiazhuang 050013,China)

机构地区：[1]河北省中医院呼吸重症科,石家庄050013 [2]河北省中医院呼吸科,石家庄050013

出　　处：《临床误诊误治》2024年第14期74-78,共5页Clinical Misdiagnosis & Mistherapy

基　　金：河北省科技厅科研计划项目(192777130D);河北省中医药管理局科研计划项目(2020052,2020025)。

摘　　要：目的评价清气化痰丸加减联合丙卡特罗治疗痰热蕴肺证支气管哮喘的临床效果。方法选取2022年1月至2023年12月收治的130例痰热蕴肺证支气管哮喘患者,采用随机数字表法分为观察组、对照组各65例,对照组采用丙卡特罗颗粒,观察组在对照组基础上加服清气化痰丸加减方,2组均服用14 d。观察2组患者临床疗效,治疗前后中医症候积分、肺功能指标[第1秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)、最大呼气流量(PEF)]、炎性因子[白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、免疫球蛋白E(IgE)]、免疫指标(CD3+、CD4+、CD8+、CD4+/CD8+)水平,以及不良反应发生情况。结果治疗后,观察组总有效率为90.77%高于对照组的7385%(P<0.05)。治疗后,2组中医证候积分较治疗前降低,且观察组低于对照组(P<0.05,P<001)。治疗后2组FEV1/FVC、FEV1、PEF均上升,且观察组FEV1/FVC、FEV1、PEF改善更显著(P<0.05,P<001)。治疗后2组IL-6、IL-8、IgE水平均较前降低,且观察组改善更显著(P<0.05,P<001)。治疗后2组CD3+、CD4+、CD4+/CD8+水平升高,CD8+水平降低,且观察组上述指标变化较对照组明显(P<0.05,P<001)。2组治疗期间均未见不良反应发生。结论采用清气化痰丸加减方联合丙卡特罗治疗痰热蕴肺证支气管哮喘患者有较好的效果,能够明显改善患者临床症状、肺功能、免疫功能,减轻气道炎症,且具有较好的安全性。Objective To evaluate the clinical effect of Qingqi Huatan pill combined with Procatterol on bronchial asthma with syndrome of phlegm-heat obstructing lung.Methods A total of 130 patients with bronchial asthma with syndrome of phlegm-heat obstructing lung admitted from January 2022 to December 2023,were divided into observation group(n=65)and control group(n=65)according to random number table method.The control group was given Procatterol Hydrochloride granules,and the observation group was supplemented with modified Qingqi Huatan pill on the basis of the control group.Both groups were treated for 14 consecutive days.Clinical efficacy,TCM symptom scores,lung function indexes[forced expiratory volume in the first second(FEV1),FEV1/forced vital capacity(FVC),and peak expiratory flow(PEF)],inflammatory factor indexes[interleukin-6(IL-6),interleukin-8(IL-8),immunoglobulin E(IgE)],immune indexes(CD3+,CD4+,CD8+,CD4+/CD8+)before and after treatment,and the occurrence of adverse drug reactions were observed in the two groups.Results The total effective rate of the observation group was 90.77%,which was higher than that in the control group(73.85%)(P<0.05).After treatment,the TCM syndrome scores of both groups were decreased compared with those before treatment,which were lower in the observation group than in the control group(P<0.05,P<0.01).The levels of FEV1/FVC,FEV1 and PEF,in both groups were significantly improved compared with those before treatment,and the chan-ges in the above indicators were more significant in the observation group(P<0.05,P<0.01).After treatment,the levels of IL-6,IL-8 and IgE were all decreased compared with the previous levels,and the changes were more significant in the obser-vation group(P<0.05,P<0.01).After treatment,the levels of CD3+,CD4+,and CD4+/CD8+were increased in both groups,while the level of CD8+was decreased;the changes in these indicators in the observation group were more sig-nificant than those in the control group(P<0.05,P<0.01).No adverse reactions were observed in each gr

关 键 词：支气管哮喘 痰热蕴肺 清气化痰丸 第1秒用力呼气容积 白细胞介素-6 CD3+ 药物毒性 

分 类 号：R562。25[医药卫生—呼吸系统]